Hi Yanzifeisheng, MSB hasn’t been a great LTH to date, but any investor should have entered knowing the high risk of (effectively) pre-revenue company in this industry. Beyond the Dream Heart results, I take it your research included the successful Phase III trial, with 9-1 vote, manufacturing inspection, ongoing compassionate use, plus second phase III for LBP underway and the planned FDA meetings this quarter? Cash reserves are very low, but isn’t the first company to be in such a position prior to potential pivotal events.
Ann: FDA Grants Orphan Drug Designation for Revascor, page-223
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26808 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 16001 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |